Read by QxMD icon Read

brunner and lupus

Ashwaq AlE'ed, Patricia Vega-Fernandez, Eyal Muscal, Claas Hinze, Lori B Tucker, Simone Appenzeller, Brigitte Bader-Meunier, Johannes Roth, Vicenç Torrente-Segarra, Marisa S Klein-Gitelman, Deborah M Levy, Tresa Roebuck-Spencer, Hermine Brunner
The diagnosis of Neuropsychiatric systemic lupus erythematosus disease (NPSLE) is challenging. The Automated Neuropsychological Assessment Metrics (ANAM) has been shown to be an accessible and promising tool for evaluating possible NPSLE in adult and childhood lupus. In this review, we present information about the development and use of Ped-ANAM; the benefit of using Ped-ANAM in children with and without NPSLE in the assessment and follow up of their disease condition; and the correlation of Ped-ANAM to imaging studies such as magnetic resonance imaging (MRI)...
December 19, 2016: Arthritis Care & Research
Scott E Wenderfer, Natasha M Ruth, Hermine I Brunner
The care of children with lupus nephritis (LN) has changed dramatically over the past 50 y. The majority of patients with childhood-onset systemic lupus erythematosus (cSLE) develop LN. In the 1960's, prognosis in children was worse than in adults; therapies were limited and toxic. Nearly half of cases resulted in death within 2 y. Since this time, several diagnostic recommendations and disease-specific indices have been developed to assist physicians caring for patients with LN. Pediatric researchers are validating and adapting these indices and guidelines for the treatment of LN in cSLE...
January 4, 2017: Pediatric Research
Tian Yu, Elena Y Enioutina, Hermine I Brunner, Alexander A Vinks, Catherine M Sherwin
Systemic lupus erythematosus (SLE) is a multifactorial autoimmune disease with potentially severe clinical manifestation that mainly affects women of child-bearing age. Patients who do not respond to standard-of-care therapies, such as corticosteroids and immunosuppressants, require biologic therapeutics that specifically target a single or multiple SLE pathogenesis pathways. This review summarizes the clinical pharmacokinetic and pharmacodynamic characteristics of biologic agents that are approved, used off-label, or in the active pipeline of drug development for SLE patients...
July 6, 2016: Clinical Pharmacokinetics
J L Huggins, M J Holland, H I Brunner
In this review we critically analyze pulmonary, gastrointestinal and cardiac manifestations of childhood-onset systemic lupus erythematosus (cSLE). Clinical manifestations of these organ systems may be the initial manifestation of cSLE; frequently occur with very active cSLE; and are potential life-threatening manifestations often presenting to the emergency department and requiring admission to the intensive care unit. Early recognition and treatment of the pulmonary, gastrointestinal and cardiac manifestations of cSLE will result in improved prognosis and better outcomes...
July 2016: Lupus
Jordan T Jones, Adam C Carle, Janet Wootton, Brianna Liberio, Jiha Lee, Laura E Schanberg, Jun Ying, Esi Morgan DeWitt, Hermine I Brunner
OBJECTIVE: To validate the pediatric Patient-Reported Outcomes Measurement Information System short forms (PROMIS-SFs) in childhood-onset systemic lupus erythematosus (SLE) in a clinical setting. METHODS: At 3 study visits, childhood-onset SLE patients completed the PROMIS-SFs (anger, anxiety, depressive symptoms, fatigue, physical function-mobility, physical function-upper extremity, pain interference, and peer relationships) using the PROMIS assessment center, and health-related quality of life (HRQoL) legacy measures (Pediatric Quality of Life Inventory, Childhood Health Assessment Questionnaire, Simple Measure of Impact of Lupus Erythematosus in Youngsters [SMILEY], and visual analog scales [VAS] of pain and well-being)...
January 2017: Arthritis Care & Research
Gaurav Gulati, Jordan T Jones, Gregory Lee, Mekibib Altaye, Dean W Beebe, Jamie Meyers-Eaton, Kasha Wiley, Hermine I Brunner, Mark W DiFrancesco
OBJECTIVE: To evaluate a safe, non-invasive MRI method to measure regional blood brain barrier (BBB) integrity and investigate its relationship with neurocognitive function and regional gray matter volume (GMV) in childhood-onset SLE (cSLE). METHODS: In this cross-sectional, case-control study, capillary permeability was measured as a marker of BBB integrity in cSLE patients and matched healthy controls, using a combination of arterial spin labeling and diffusion-weighted brain MRI...
April 25, 2016: Arthritis Care & Research
K M Abulaban, H Song, X Zhang, P L Kimmel, J W Kusek, R G Nelson, H I Feldman, R S Vasan, J Ying, M Mauer, G L Nelsestuen, M Bennett, H I Brunner, B H Rovin
OBJECTIVE: To evaluate candidate biomarkers to predict future renal function decline (RFD) in children and adults with lupus nephritis (LN). METHODS: At the time of enrollment into prospective observational LN cohort studies liver-type fatty acid binding protein (LFABP), albumin, monocyte chemoattractant protein-1 (MCP-1), uromodulin, transferrin, and hepcidin were measured in urine samples of two cohorts of patients with LN, one followed at a pediatric (cohort-1; n = 28) and one at an adult institution (cohort-2; n = 69)...
August 2016: Lupus
Khalid M Abulaban, Ndate Fall, Ravi Nunna, Jun Ying, Prasad Devarajan, Alexi Grom, Michael Bennett, Stacy P Ardoin, Hermine I Brunner
BACKGROUND: MicroRNAs (miRNAs) are involved in the post-transcriptional regulation of genes. The objective of this study was to investigate whether select urinary cell-free microRNA's may serve as biomarkers in children with active lupus nephritis (LN) and to assess their relationship to the recently identified combinatorial urine biomarkers, a.k.a. the LN-Panel (neutrophil gelatinase associated lipocalin, monocyte chemotactic protein 1, transferrin, and beta-trace protein). METHODS: miRNAs (125a, 127, 146a, 150 and 155) were measured using real-time polymerase chain reaction in the urine pellet (PEL) and supernatant (SUP) in 14 patients with active LN, 10 patients with active extra-renal lupus, and 10 controls...
January 14, 2016: Pediatric Rheumatology Online Journal
Georgios Nikolakis, Ioannis Karagiannidis, Vasiliki A Zampeli, Andreas Altenburg, Martina Brunner, Christos C Zouboulis
Human papilloma virus (HPV) infection is documented to be involved in the development of epithelial malignancies, mostly in cervical cancer. Systemic lupus erythematosus (SLE) patients have an increased prevalence of such an infection. We report the case of a 55-year-old female SLE patient who developed multiple in situ squamous cell carcinomas on her fingers, after chronic HPV infection. HPV-33 DNA was isolated from the lesions. The purpose of this case presentation is to raise awareness about HPV-induced malignancies for this high-risk group and propose an early HPV vaccination to efficiently prevent such comorbidities...
September 2015: Case Reports in Dermatology
Hermine I Brunner, Michael R Bennett, Khalid Abulaban, Marisa S Klein-Gitelman, Kathleen M O'Neil, Lori Tucker, Stacy P Ardoin, Kelly A Rouster-Stevens, Karen B Onel, Nora G Singer, B Anne Eberhard, Lawrence K Jung, Lisa Imundo, Tracey B Wright, David Witte, Brad H Rovin, Jun Ying, Prasad Devarajan
OBJECTIVE: Noninvasive estimation of the degree of inflammation seen on kidney biopsy with lupus nephritis (LN) remains difficult. The objective of this study was to develop a Renal Activity Index for Lupus (RAIL) that, based solely on laboratory measures, accurately reflects histologic LN activity. METHODS: We assayed traditional LN laboratory tests and 16 urine biomarkers (UBMs) in children (n = 47) at the time of kidney biopsy. Histologic LN activity was measured by the National Institutes of Health activity index (NIH-AI) and the tubulointerstitial activity index (TIAI)...
July 2016: Arthritis Care & Research
Heinrike Schmeling, Michael Mahler, Deborah M Levy, Katharine Moore, Anne M Stevens, James Wick, Jacob D McMillan, Gerd Horneff, Shervin Assassi, Julio Charles, Gloria Salazar, Maureen D Mayes, Earl D Silverman, Marissa Klien-Gitelman, Tzelan Lee, Hermine I Brunner, Ann M Reed, Marvin J Fritzler
OBJECTIVE: Autoantibodies to the dense fine speckled 70 kDa antigen (DFS70) are reported to be more common in individuals who do not have an antinuclear antibody (ANA)-associated rheumatic disease (AARD) than in patients with AARD. The frequency of anti-DFS70 antibodies has been thoroughly studied in adult but not in pediatric populations. The primary objective of this observational study was to determine the frequency of anti-DFS70 in pediatric AARD and reference cohorts. METHODS: Sera from 743 children with AARD and related conditions, and 345 samples from reference cohorts (healthy children and those being investigated for AARD) were studied for anti-DFS70 autoantibodies as measured by a chemiluminescence immunoassay...
December 2015: Journal of Rheumatology
Rina Mina, Julia G Harris, Marisa S Klein-Gitelman, Simone Appenzeller, Maraisa Centeville, Diane Eskra, Jennifer L Huggins, Anne L Johnson, Raju Khubchandani, Prachi Khandekar, Jiha Lee, Hai Mei Liu, Joshua D Pendl, Clovis A Silva, Marco F Silva, Ahmad I Zaal, Esi Morgan DeWitt, Stacy P Ardoin, Hermine I Brunner
OBJECTIVE: To assess the quality of medical care in childhood-onset systemic lupus erythematosus (SLE) at tertiary pediatric rheumatology centers as measured by observance of SLE quality indicators (SLE-QIs). METHODS: International consensus has been achieved for childhood-onset SLE-QIs capturing medical care provision in 9 domains: diagnostic testing, education of cardiovascular (CV) risk and lifestyles, lupus nephritis (LN), medication management, bone health, ophthalmologic surveillance, transition, pregnancy, and vaccination...
February 2016: Arthritis Care & Research
Rina Mina, Khalid Abulaban, Marisa S Klein-Gitelman, Barbara A Eberhard, Stacy P Ardoin, Nora Singer, Karen Onel, Lori Tucker, Kathleen O'neil, Tracey Wright, Elizabeth Brooks, Kelly Rouster-Stevens, Lawrence Jung, Lisa Imundo, Brad Rovin, David Witte, Jun Ying, Hermine I Brunner
OBJECTIVE: To validate clinical indices of lupus nephritis activity and damage when used in children against the criterion standard of kidney biopsy findings. METHODS: In 83 children requiring kidney biopsy, the Systemic Lupus Erythematosus Disease Activity Index renal domain (SLEDAI-R), British Isles Lupus Assessment Group index renal domain (BILAG-R), Systemic Lupus International Collaborating Clinics (SLICC) renal activity score (SLICC-RAS), and SLICC Damage Index renal domain (SDI-R) were measured...
February 2016: Arthritis Care & Research
Jordan T Jones, Natoshia Cunningham, SusmitA Kashikar-Zuck, Hermine I Brunner
OBJECTIVE: To evaluate pain, fatigue, and psychological functioning of childhood-onset systemic lupus erythematosus (SLE) patients and examine how these factors impact health-related quality of life (HRQOL). METHODS: At a tertiary rheumatology clinic, 60 childhood-onset SLE patients completed the following: a visual analog scale (VAS) of pain intensity (0-10), the Pediatric Quality of Life (PedsQL) multidimensional fatigue scale, Pain Coping Questionnaire, Pain Catastrophizing Scale (PCS), Children's Depression Inventory I (CDI-I), the Screen for Child Anxiety Related Emotional Disorders (SCARED) questionnaire, and the PedsQL generic core (GC) scale and rheumatology module (RM)...
January 2016: Arthritis Care & Research
Xiaoyan Yang, Catherine M T Sherwin, Tian Yu, Venkata K Yellepeddi, Hermine I Brunner, Alexander A Vinks
With the increasing use of different types of therapies in treating autoimmune diseases such as systemic lupus erythematosus (SLE), there is a need to utilize pharmacokinetic (PK) strategies to optimize the clinical outcome of these treatments. Various PK analysis approaches, including population PK modeling and physiologically based PK modeling, have been used to evaluate drug PK characteristics and population variability or to predict drug PK profiles in a mechanistic manner. This review outlines the PK modeling of major SLE therapies including immunosuppressants (methotrexate, azathioprine, mycophenolate and cyclophosphamide, among others) and immunomodulators (intravenous immunoglobulin)...
2015: Expert Review of Clinical Pharmacology
Patricia Vega-Fernandez, Shana Vanderburgh White, Frank Zelko, Natasha M Ruth, Deborah M Levy, Eyal Muscal, Marisa S Klein-Gitelman, Adam M Huber, Lori B Tucker, Tresa Roebuck-Spencer, Jun Ying, Hermine I Brunner
OBJECTIVE: To develop and initially validate a global cognitive performance score (CPS) for the Pediatric Automated Neuropsychological Assessment Metrics (PedANAM) to serve as a screening tool of cognition in childhood lupus. METHODS: Patients (n = 166) completed the 9 subtests of the PedANAM battery, each of which provides 3 principal performance parameters (accuracy, mean reaction time for correct responses, and throughput). Cognitive ability was measured by formal neurocognitive testing or estimated by the Pediatric Perceived Cognitive Function Questionnaire-43 to determine the presence or absence of neurocognitive dysfunction (NCD)...
August 2015: Arthritis Care & Research
J T Jones, M DiFrancesco, A I Zaal, M S Klein-Gitelman, D Gitelman, J Ying, H I Brunner
OBJECTIVES: The objective of this report is to use diffusion-tensor imaging (DTI) for investigating white-matter connectivity changes associated with neurocognitive dysfunction in childhood-onset lupus (cSLE-NCD) as measured by formal neuropsychological testing. METHODS: DTI was performed in six individuals with (cSLE-NCD) and nine without neurocognitive dysfunction (cSLE-noNCD) as well as 14 healthy controls. Presence of neurocognitive deficits was identified by formal neuropsychological testing...
September 2015: Lupus
Hermine I Brunner, Clovis A Silva, Andreas Reiff, Gloria C Higgins, Lisa Imundo, Calvin B Williams, Carol A Wallace, Nadia E Aikawa, Shannen Nelson, Marisa S Klein-Gitelman, Susan R Rose
OBJECTIVE: To determine the dose of triptorelin that is sufficient to maintain complete ovarian suppression in female patients with childhood-onset systemic lupus erythematosus (SLE) who require cyclophosphamide therapy, to determine the length of time needed to achieve ovarian suppression after initiation of triptorelin treatment, and to investigate the safety of triptorelin. METHODS: In this randomized, double-blind, placebo-controlled, dose-escalation study, female patients ages <21 years were randomized 4:1 to receive triptorelin (n = 25) or placebo (n = 6)...
May 2015: Arthritis & Rheumatology
Khalid M Abulaban, Hermine I Brunner
Childhood-onset systemic lupus erythematosus (cSLE) is a systemic autoimmune disease characterized by the presence of autoantibodies. cSLE often affects multiple organs in the body and is known to have a poorer prognosis than adult-onset disease (Azevedo et al. 2014). Current laboratory tests are clearly insufficient for identifying and monitoring the disease. Recent studies have yielded novel biomarkers for cSLE which can be used for monitoring disease activity and response to treatment. The most encouraging biomarkers will be discussed herein and include cell-bound complement activation products, some genomic profiles, and urinary proteins such as neutrophil gelatinase-associated lipocalin, monocyte chemoattractant protein-1, and others...
January 2015: Current Rheumatology Reports
Hermine I Brunner, Marisa S Klein-Gitelman, Frank Zelko, Dean W Beebe, Dirk Foell, Jiha Lee, Ahmad Zaal, Jordan Jones, Tresa Roebuck-Spencer, Jun Ying
OBJECTIVE: To examine select brain-reactive proteins for their usefulness to serve as blood-based biomarkers in the screening for neurocognitive deficits in childhood-onset systemic lupus erythematosus (cSLE-NCD). METHODS: Patients withcSLE (n=40) were studied longitudinally (month 1; month 18): working memory, psychomotor speed and visuoconstructional ability were assessed using formal neurocognitive testing to determine the presence of cSLE-NCD. Patients also completed the computerised Paediatric Automated Neuropsychological Assessment Metrics...
2014: Lupus Science & Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"